Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Cedars-Sinai performed the first robot-assisted microsurgical head-and-neck cancer reconstructive surgery in the United States after the robot device received FDA approval for the procedure.

February 21, 2025

Vol.51 No.07

Guest Editorial

From the chairs of ECOG-ACRIN: A perspective on indirect costs

Indirect costs are a component of a grant award that recognizes expenses for a project that, for efficiency’s sake, are aggregated across projects and divided proportionally to projects rather than explicitly charged to each project. They are influenced by location and services provided.

February 14, 2025

Vol.51 No.06

By Peter J. O'Dwyer and Mitchell D. Schnall

Guest Editorial

Cedars-Sinai Cancer’s model of care ensured patient care amid wildfires

Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history.

January 17, 2025

Vol.51 No.02

By Dan Theodorescu, Robert A. Figlin, Howard M. Sandler and Joan August

Clinical Roundup

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

The Groupe d’Oncologie Radiothérapie Tête Et Cou, also known as the Head and Neck Oncology and Radiotherapy Group or GORTEC, announced that the randomized phase III CheckMate -9KW/NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab (Opdivo) as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck with high risk of relapse met its primary endpoint of disease-free survival across all comers.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Temozolomide + radiation treatment improves OS for grade 2 gliomas

Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas.

December 06, 2024

Vol.50 No.45

Clinical Roundup

More cancers being treated with personalized therapies before surgery, National Cancer Database report shows

Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person’s survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database.

December 06, 2024

Vol.50 No.45

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

YOU MAY BE INTERESTED IN

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

From the chairs of ECOG-ACRIN: A perspective on indirect costs

Cedars-Sinai Cancer’s model of care ensured patient care amid wildfires

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

Temozolomide + radiation treatment improves OS for grade 2 gliomas

More cancers being treated with personalized therapies before surgery, National Cancer Database report shows

Renew today!

Subscriber content

Never miss an issue!

Login